Clinical Trial Update: A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial comparing switching from tiotropium to QVA149 (indacaterol/glycopyrronium) in symptomatic mild-to-moderate COPD patients; results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA149 (indacaterol/glycopyrronium)
• tiotropium (tiotropium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: COPD | Phase 4 | Status: COMPLETED | Results posted: 2019-09-23